LMR Partners’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

LMR Partners’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$505K	–	1280
2022 Q4	$505K	Hold	50,000	–	–	0.01%	871
2022 Q3	$496K	Hold	50,000	–	–	0.01%	874
2022 Q2	$495K	Hold	50,000	–	–	0.01%	912
2022 Q1	$493K	Hold	50,000	–	–	0.01%	974
2021 Q4	$492K	Hold	50,000	–	–	0.01%	894
2021 Q3	$487K	Hold	50,000	–	–	0.01%	793
2021 Q2	$43K	Buy	+50,000	New	+$34.8K	﹤0.01%	1010

LMR Partners's BIOTW Position: Q1 2023 in Review

LMR Partners sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 50,000 shares — an estimated $505K sold.

LMR Partners first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $505K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

LMR Partners reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
LMR Partners sold 50,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $505K.
LMR Partners first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
LMR Partners's Biotech Acquisition Company Warrant position peaked at $505K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.